Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Curr Diab Rep ; 15(8): 53, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26084582

RESUMEN

Youth receiving treatment with antipsychotics are particularly susceptible to weight gain, type 2 diabetes (T2D), and associated metabolic disorders, which is directly associated with excess morbidity and mortality in this vulnerable population. The risk of T2D is 2- to 3-fold that of the general population, starts early in the course of treatment, and reflects the effects of weight gain in conjunction with direct effects of antipsychotics on the hypothalamus, pancreatic beta cells, and insulin-sensitive peripheral tissues. Close monitoring with early intervention through lifestyle intervention, switching away from antipsychotics with deleterious metabolic effects, and adjunctive treatment with metformin are modalities available to mitigate weight gain and improve cardiometabolic health in these patients. Despite rapidly advancing knowledge in the field, patient's access to metabolic screening and quality care remains limited. Efforts must be made to broaden reach of early cardiometabolic intervention among these patients in order to avert serious cardiovascular disease burden in the future.


Asunto(s)
Antipsicóticos/efectos adversos , Diabetes Mellitus Tipo 2/inducido químicamente , Adolescente , Niño , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Humanos , Insulina/metabolismo , Estilo de Vida , Obesidad/inducido químicamente , Aumento de Peso/efectos de los fármacos
2.
J Gastrointest Surg ; 25(2): 369-377, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33420652

RESUMEN

BACKGROUND: Bariatric surgery is the most effective treatment for obesity; however, some patients experience significant weight regain. Weight loss medications (WLM) are being increasingly used in surgery patients with limited evidence. We examine weight loss outcomes in patients using WLM after bariatric surgery. METHODS: In a retrospective study, 197 bariatric surgery patients who started WLM between 2016 and 2019 at a single center were analyzed. Patients were categorized into 3 groups based on outcomes of the initial surgery: (1) Weight regainers (WR) = achieved goal weight loss after surgery (15% total body weight loss (TBWL) for sleeve gastrectomy (SG) and 25% TBWL for Roux-en-Y gastric bypass (RYGB)) with subsequent regain of > 20% of weight lost; (2) Adequate weight loss (AWL) = achieved goal weight loss without > 20% weight regain; (3) Non-responders (NR) = never achieved goal weight loss. Weight loss and medication use patterns were analyzed. RESULTS: Among the three categories, there was no significant difference in duration of medical therapy or %TBWL with medications. RYGB patients lost more weight than SG patients using WLM (p = 0.03). Of the medications used, patients treated with phentermine + topiramate had the highest likelihood of achieving 5%, 10%, and 15% weight loss. Compared to other 2 groups, AWL group initiated WLM earlier and experienced more weight loss when compared to their pre-operative weight or post-operative nadir. CONCLUSIONS: RYGB patients respond better to WLM than SG patients. Those who had started WLM before regaining weight (AWL) experienced greater overall weight loss, suggesting that proactive medical therapy at the time of weight plateau can help with greater total weight loss. Phentermine + topiramate is the most effective WLM in post-bariatric surgery patients.


Asunto(s)
Cirugía Bariátrica , Derivación Gástrica , Obesidad Mórbida , Gastrectomía , Humanos , Obesidad Mórbida/cirugía , Estudios Retrospectivos , Pérdida de Peso
3.
Curr Diab Rep ; 9(5): 348-54, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19793504

RESUMEN

Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes mellitus (T2DM). In obesity, the adipose cell releases nonesterified free fatty acids, hormones, adipocytokines, and other substances that are involved in insulin resistance. Under normal conditions, the pancreatic islet beta cells increase production of insulin sufficiently to maintain normal blood glucose concentrations despite insulin resistance. However, in genetically predisposed patients, the beta cells eventually become dysfunctional and T2DM develops. The development of T2DM can be delayed or sometimes prevented in individuals with obesity who are able to lose weight. Weight loss can be achieved medically with behavioral therapies that combine diet and exercise treatment or with behavioral therapies combined with weight-loss medications or weight-loss surgery. In this article, we summarize the evidence of obesity management in treating T2DM and prediabetes.


Asunto(s)
Diabetes Mellitus Tipo 2/terapia , Obesidad/terapia , Estado Prediabético/terapia , Fármacos Antiobesidad/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/prevención & control , Humanos , Obesidad/tratamiento farmacológico , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/prevención & control , Pérdida de Peso/efectos de los fármacos , Pérdida de Peso/fisiología
4.
Menopause ; 15(1): 125-32, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18257146

RESUMEN

OBJECTIVE: The aim of this study was to determine the effect of DRIs on hot flash symptoms in menopausal women. DESIGN: This was a randomized, double-blind, placebo-controlled trial of menopausal women, aged 38 to 60 years, who experienced 4 to 14 hot flashes per day. After a 1-week run-in period, a total of 190 menopausal women were randomized to receive a placebo or 40 or 60 mg/day of a DRI for 12 weeks. The primary outcome was the mean changes from baseline to week 12 in the frequency of hot flashes recorded in the participant diary. The secondary outcomes included changes in quality of life and hormonal profiles. RESULTS: A total of 147 women (77%) completed the study. It was found that 40 and 60 mg of DRI improved hot flash frequency and severity equally. At 8 weeks hot flash frequency was reduced by 43% in the 40-mg DRI group and by 41% in the 60-mg DRI group, compared with 32% in the placebo group (P = not significant vs placebo). The corresponding numbers for 12 weeks were 52%, 51%, and 39%, respectively (P = 0.07 and 0.09 vs placebo). When comparing the two treatment groups with the placebo group, there were significant reductions in mean daily hot flash frequency. The supplement (either 40 or 60 mg) reduced hot flash frequency by 43% at 8 weeks (P = 0.1) and 52% at 12 weeks (P = 0.048) but did not cause any significant changes in endogenous sex hormones or thyroid hormones. Menopausal quality of life improved in all three groups, although there were no statistically significant differences between groups. CONCLUSIONS: DRI supplementation may be an effective and acceptable alternative to hormone treatment for menopausal hot flashes.


Asunto(s)
Sofocos/tratamiento farmacológico , Isoflavonas/administración & dosificación , Menopausia/efectos de los fármacos , Fitoestrógenos/administración & dosificación , Calidad de Vida , Adulto , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Isoflavonas/farmacología , Satisfacción del Paciente , Fitoestrógenos/farmacología , Extractos Vegetales/administración & dosificación , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
5.
J Am Diet Assoc ; 108(4 Suppl 1): S40-4, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18358255

RESUMEN

Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes. Development of type 2 diabetes can be delayed or sometimes prevented from manifestation in individuals with obesity that are able to lose weight. Weight loss can be achieved either medically with behavioral therapies that combine diet and exercise treatment or with behavioral therapies combined with weight-loss medications or weight-loss surgery. There is strong evidence of an amelioration or resolution of type 2 diabetes in patients undergoing gastric bypass surgery. A recently published retrospective cohort study indicated that long-term total mortality from diabetes, heart disease, and cancer after gastric bypass surgery was substantially reduced. In this review, we summarize the evidence of surgical interventions in the treatment of type 2 diabetes.


Asunto(s)
Cirugía Bariátrica/efectos adversos , Cirugía Bariátrica/métodos , Diabetes Mellitus Tipo 2/prevención & control , Obesidad Mórbida/cirugía , Medición de Riesgo , Cirugía Bariátrica/mortalidad , Derivación Gástrica/métodos , Humanos , Resistencia a la Insulina , Obesidad Mórbida/complicaciones , Pérdida de Peso/fisiología
6.
Manag Care Interface ; 20(5): 24-31, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17626588

RESUMEN

The prevalence of obesity and overweight is rising among adults and children. Ample evidence indicates that weight loss, even if moderate, can improve health status and lessen the incidence of obesity-related disease. A variety of treatments are available to deal with the condition. However, no matter what therapy is chosen, the patient must be aware that success may depend on adherence and follow-up with a health care practitioner.


Asunto(s)
Obesidad/terapia , Fármacos Antiobesidad , Terapia Conductista , Dieta Baja en Carbohidratos , Dieta con Restricción de Grasas , Derivación Gástrica , Humanos , Encuestas Nutricionales , Obesidad/complicaciones , Obesidad/epidemiología , Prevalencia , Estados Unidos/epidemiología
7.
Diabetes ; 54(1): 204-11, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15616030

RESUMEN

We examined the effects of high-dosage vitamin E treatment over a 12-month period on the vascular reactivity of micro- and macrocirculation and left ventricular function in diabetic patients. Subjects (n = 89) were randomized to vitamin E (1,800 IU daily) or placebo and were followed for 12 months. High-resolution ultrasound images were used to measure the flow-mediated dilation (FMD; endothelium dependent) and nitroglycerin-induced dilation (NID; endothelium independent) of the brachial artery. Laser Doppler perfusion imaging was used to measure vascular reactivity in the forearm skin. Left ventricular function was evaluated using transthoracic echocardiogram. At the end of the 6-month period, a worsening in endothelium-dependent skin vasodilation (P = 0.02) and rise in endothelin levels (P = 0.01) were found in the vitamin E compared with the placebo group. At the end of the 12-month period, a worsening was observed in NID (P = 0.02) and a marginal worsening was seen in systolic blood pressure (P = 0.04) and FMD (P = 0.04) in the vitamin E compared with the placebo group. In addition C-reactive protein levels decreased marginally in the vitamin E compared with the placebo group (P = 0.05). No changes were observed in left ventricular function. We concluded that long-term treatment with 1,800 IU of vitamin E has no beneficial effects on endothelial or left ventricular function in diabetic patients. Because vitamin E-treated patients had a worsening in some vascular reactivity measurements when compared with control subjects, the use of high dosages of vitamin E cannot be recommended.


Asunto(s)
Circulación Sanguínea/fisiología , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/fisiopatología , Endotelio Vascular/fisiopatología , Función Ventricular Izquierda/fisiología , Vitamina E/farmacología , Adulto , Albuminuria , Circulación Sanguínea/efectos de los fármacos , Glucemia/metabolismo , Presión Sanguínea/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Función Ventricular Izquierda/efectos de los fármacos
8.
Lancet ; 366(9498): 1711-7, 2005 Nov 12.
Artículo en Inglés | MEDLINE | ID: mdl-16291064

RESUMEN

BACKGROUND: Changes in the large vessels and microcirculation of the diabetic foot are important in the development of foot ulceration and subsequent failure to heal existing ulcers. We investigated whether oxygen delivery and muscle metabolism of the lower extremity were factors in diabetic foot disease. METHODS: We studied 108 patients (21 control individuals who did not have diabetes, 36 patients with diabetes who did not have neuropathy, and 51 patients with both diabetes and neuropathy). We used medical hyperspectral imaging (MHSI) to investigate the haemoglobin saturation (S(HSI)O2; % of oxyhaemoglobin in total haemoglobin [the sum of oxyhaemoglobin and deoxyhaemoglobin]) in the forearm and foot; we also used 31P-MRI scans to study the cellular metabolism of the foot muscles by measuring the concentrations of inorganic phosphate and phosphocreatine and calculating the ratio of inorganic phosphate to phosphocreatine (Pi/PCr). FINDINGS: The forearm S(HSI)O2 during resting was different in all three groups, with the highest value in controls (mean 42 [SD 17]), followed by the non-neuropathic (32 [8]) and neuropathic (28 [8]) groups (p<0.0001). In the foot at resting, S(HSI)O2 was higher in the control (38 [22]) and non-neuropathic groups (37 [12]) than in the neuropathic group (30 [12]; p=0.027). The Pi/PCr ratio was higher in the non-neuropathic (0.41 [0.10]) and neuropathic groups (0.58 [0.26]) than in controls (0.20 [0.06]; p<0.0001). INTERPRETATION: Our results indicate that tissue S(HSI)O2 is reduced in the skin of patients with diabetes, and that this impairment is accentuated in the presence of neuropathy in the diabetic foot. Additionally, energy reserves of the foot muscles are reduced in the presence of diabetes, suggesting that microcirculation could be a major reason for this difference.


Asunto(s)
Pie Diabético/metabolismo , Músculo Esquelético/metabolismo , Oxígeno/metabolismo , Piel/irrigación sanguínea , Estudios de Casos y Controles , Diabetes Mellitus/metabolismo , Neuropatías Diabéticas/metabolismo , Femenino , Antebrazo , Humanos , Masculino , Microcirculación , Persona de Mediana Edad
9.
Diabetes Care ; 28(6): 1425-30, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15920063

RESUMEN

OBJECTIVE: To characterize structural changes and the metabolic profile of foot muscles and correlate them with diabetic neuropathy measurements using phosphorus-31 ((31)P) rapid acquisition with relaxation enhancement (RARE) magnetic resonance imaging (MRI). RESEARCH DESIGN AND METHODS: We studied 12 control subjects, 9 non-neuropathic diabetic patients, and 12 neuropathic diabetic patients using (31)P RARE and proton ((1)H) MRI at 3 Tesla. The ratio of the total cross-sectional area of the foot to that of the muscle tissue was calculated from transaxial (1)H and (31)P images. The average (31)P concentration across the metatarsal head region was measured from the (31)P images. RESULTS: The muscle area-to-total area ratio differed among all three groups (means +/- SD): 0.55 +/- 0.04 vs. 0.44 +/- 0.05 vs. 0.06 +/- 0.06 for control, non-neuropathic, and neuropathic subjects, respectively (P < 0.0001). The average (31)P concentration also differed among all groups: 27.7 +/- 3.8 vs. 21.7 +/- 4.8 vs. 7.9 +/- 8.8 mmol/l for control, non-neuropathic, and neuropathic subjects (P < 0.0001). The muscle area-to-total area ratio strongly correlated with clinical measurements: Neuropathy Disability Score, r = -0.83, P < 0.0001; vibration perception threshold, r = -0.79, P < 0.0001; and Semmes-Weinstein monofilaments, r = -0.87, P < 0.0001. CONCLUSIONS: Small muscle atrophy is present in diabetes before clinical peripheral neuropathy can be detected using standard clinical techniques. The (31)P RARE MRI method evaluates the severity of muscle atrophy, even in the early stages when neuropathy is absent. This technique may prove to be a useful diagnostic tool in identifying early-stage diabetic foot problems.


Asunto(s)
Atrofia/patología , Neuropatías Diabéticas/patología , Músculo Esquelético/patología , Índice de Masa Corporal , Pie Diabético/diagnóstico , Femenino , Pie , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Tritio
10.
Diabetes Care ; 26(12): 3280-3, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14633814

RESUMEN

OBJECTIVE: Localized low-level mechanical or electrical noise can significantly enhance tactile sensitivity in healthy young subjects and older adults. This phenomenon is termed stochastic resonance (SR). In this study, we examined the effect of SR on vibratory and tactile sensation in patients with moderate to severe diabetic peripheral neuropathy. RESEARCH DESIGN AND METHODS: A total of 20 subjects were included in the study. The vibration perception threshold (VPT) test and the Semmes-Weinstein filament (SWF) threshold at the plantar surface of the left foot and the big toe were determined under two mechanical noise stimulus conditions: null (no noise) condition and at 10% lower than each subject's mechanical noise threshold of perception. RESULTS: The baseline values (mean +/- SD) were as follows: Neuropathy Symptom Score (NSS) 5.2 +/- 2.5, Neuropathy Disability Score (NDS) 5.0 +/- 2.1, VPT 24 +/- 11 V, and SWF threshold 5.6 +/- 0.8 at the plantar surface of the foot and 5.3 +/- 0.9 at the big toe. The VPT improved significantly from 24 +/- 11 under null condition to 19 +/- 10 V with mechanical noise (P < 0.0001). Mechanical noise also significantly increased the number of detections of the SWF at the plantar surface of the foot (detection rate 66 +/- 11 vs. 59 +/- 15%, P < 0.02) but not at the big toe (63 +/- 10 vs. 61 +/- 16%, P = NS). CONCLUSIONS: Mechanical noise stimulation improves vibration and tactile perception in diabetic patients with moderate to severe neuropathy. Additional studies are required to examine the effect of long-term noise stimulation on parameters of nerve function.


Asunto(s)
Pie Diabético/fisiopatología , Neuropatías Diabéticas/fisiopatología , Percepción/fisiología , Estimulación Física , Sensación/fisiología , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ruido , Dedos del Pie/fisiología , Vibración
11.
J Clin Endocrinol Metab ; 89(2): 740-7, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14764790

RESUMEN

We have investigated the effect of atorvastatin on the endothelial function of patients with diabetes and subjects at risk for type 2 diabetes in a 12-wk, prospective, randomized, placebo-controlled, double-blind clinical trial. The flow- mediated dilation (FMD; endothelium dependent) and nitroglycerin-induced dilation (endothelium independent) in the brachial artery and the vascular reactivity at the forearm skin were measured. FMD improved in the atorvastatin-treated, at-risk subjects [median (25-75 percentile), 7.2% (2.9-9.6%) at exit visit vs. 6.6% (2.9-9.5%) at baseline; P < 0.05]. A similar improvement of FMD was found in atorvastatin-treated diabetic patients [median (25-75 percentile), 5.6 (3.9-7.9) at exit visit vs. 4.2 (3.2-7.2) at baseline; P = 0.07]. No changes were observed in nitroglycerin-induced dilation and the microcirculation reactivity measurements in either group. In the at-risk group, there was a decrease in the C-reactive protein [median (25-75 percentile), 0.12 mg/dl (0.07-0.27 mg/dl) at exit visit vs. 0.24 mg/dl (0.07-0.35 mg/dl) at baseline; P < 0.05] and TNF alpha [median (25-75 percentile), 2.6 pg/ml (1.8-4.1 pg/ml) at exit visit vs. 4.4 pg/ml (3.6-6.0 pg/ml) at baseline; P < 0.05] in the atorvastatin-treated patients, whereas in the diabetes group, a decrease in endothelin-1 (mean +/- SD, 0.97 +/- 0.29 pg/ml at exit visit vs. 1.19 +/- 0.42 pg/ml at baseline; P < 0.05) and plasminogen activator inhibitor-1 [median (25-75 percentile), 18 ng/ml (9-24 ng/ml) at exit visit vs. 27 ng/ml (7-41 ng/ml) at baseline; P < 0.05] were observed. We conclude that atorvastatin improves endothelial function and decreases levels of markers of endothelial activation and inflammation.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/fisiopatología , Endotelio Vascular/fisiopatología , Ácidos Heptanoicos/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Pirroles/uso terapéutico , Adulto , Atorvastatina , Biomarcadores/sangre , Arteria Braquial , Diabetes Mellitus Tipo 2/etiología , Método Doble Ciego , Endotelio Vascular/efectos de los fármacos , Femenino , Antebrazo , Humanos , Inflamación/sangre , Masculino , Microcirculación/efectos de los fármacos , Persona de Mediana Edad , Nitroglicerina/farmacología , Flujo Sanguíneo Regional , Factores de Riesgo , Piel/irrigación sanguínea , Vasodilatación , Vasodilatadores/farmacología
12.
Metabolism ; 53(2): 222-7, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14767875

RESUMEN

The aim of the present study was to examine the relationship among water diuresis-induced changes in renal oxygenation, endothelial function, and various metabolic parameters in type 2 diabetic patients and healthy subjects at risk of type 2 diabetes. Thirty-eight subjects with type 2 diabetes (D: age, 54 +/- 10 years, mean +/- SD, 24 men) and 7 healthy subjects with parental history of type 2 diabetes or with impaired glucose tolerance (IGT) (relatives [R]: age 46 +/- 11 years, 4 men) were included. Laser Doppler imaging scanning was used to measure vasodilatation in the forearm skin in response to iontophoresis of 1% acetylcholine (Ach) and 1% sodium nitroprusside (SNP), and ultrasound was used to measure the flow-mediated dilation (FMD) and nitroglycerin-induced dilation (NID) in the brachial artery. Renal oxygenation was assessed by magnetic resonance imaging (MRI) before and during water diuresis. A decrease in the magnetic parameter R2* implies an increase in oxygenation. Renal medullary oxygenation did not improve with diuresis in either group (D: -0.5 +/- 1.9, R: -0.4 +/- 2.1, P = not significant [NS]). The renal cortical oxygenation showed a small, but statistically significant, improvement after diuresis in the 2 groups (D: -0.6 +/- 1.1, R: -0.5 +/- 0.5, P <.05). There were no correlations between the change in cortical R2* (R2* post-minus R2* prewater diuresis) and the micro- and macrovascular reactivity. The postdiuresis renal cortical R2* was negatively correlated with both the Ach- and SNP-induced skin vasodilation (% change over baseline)(r = -.40, P <.01 and r = -.39, P <.05, respectively), while no correlation existed with the FMD and NID. The baseline renal cortical oxygenation was also negatively correlated with the SNP-induced skin vasodilation (r = -.36, P <.05) and positively correlated with the fasting plasma glucose, total cholesterol, and vascular cell adhesion molecule (VCAM) concentrations (r =.34, P <.05, r =.31, P <.05 and r =.37, P <.05, respectively). These preliminary findings suggest an association between the kidney cortical oxygenation and the skin microvascular reactivity, glycemia, and lipidemia. Water diuresis failed to produce an improvement in renal medullary oxygenation in both patients with diabetes and subjects at risk for diabetes.


Asunto(s)
Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/metabolismo , Diuresis/fisiología , Endotelio Vascular/fisiología , Riñón/metabolismo , Consumo de Oxígeno/fisiología , Agua/farmacología , Anciano , Arteria Braquial/fisiología , Diuresis/efectos de los fármacos , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Corteza Renal/metabolismo , Médula Renal/metabolismo , Imagen por Resonancia Magnética , Masculino , Microcirculación/fisiología , Persona de Mediana Edad , Oxígeno/sangre , Flujo Sanguíneo Regional/fisiología , Factores de Riesgo , Piel/irrigación sanguínea , Vasodilatación/fisiología
13.
J Diabetes Complications ; 17(4): 205-10, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12810244

RESUMEN

OBJECTIVE: To evaluate the vasodilation induced by topical application of methyl nicotinate (MN) and to compare it with the vasodilatory response to acetylcholine (ACh) and sodium nitroprusside (SNP) in healthy subjects and diabetic neuropathic patients. RESEARCH DESIGN AND METHODS: Ten diabetic patients with peripheral neuropathy (DN) and 10 age- and sex-matched healthy control subjects (C) were enrolled. The vasodilatory response to topical application of 1% MN and a placebo emulsion at the forearm and dorsum of the foot skin at 5, 15, 30, 60 and 120 min was measured using Laser Doppler Perfusion Imaging. The vasodilatory response to iontophoresis of 1% ACh and 1% SNP solutions was also evaluated. RESULTS: The maximal vasodilatory response to ACh, SNP and MN was similar at the forearm and foot level in the diabetic patients. In the control group, the responses to MN, ACh and SNP were similar on the forearm but in the foot, the MN vasodilatory response was higher when compared to the ACh and SNP responses. MN-related vasodilation was present 5 min after the application, reached its peak at 15-30 min and declined to pre-application levels 120 min afterward. CONCLUSIONS: Topical application of MN at the forearm and foot levels of diabetic neuropathic patients results in skin vasodilation that is comparable to the maximal vasodilation that can be induced by iontophoresis of ACh or SNP and lasts for less than 2 h. Further studies will be required to explore the potential of MN to increase blood flow and to prevent diabetic foot problems in clinical practice.


Asunto(s)
Neuropatías Diabéticas/tratamiento farmacológico , Neuropatías Diabéticas/fisiopatología , Ácidos Nicotínicos/administración & dosificación , Piel/irrigación sanguínea , Vasodilatación , Vasodilatadores/administración & dosificación , Acetilcolina/administración & dosificación , Administración Tópica , Adulto , Estudios de Casos y Controles , Femenino , Pie , Antebrazo , Humanos , Iontoforesis , Flujometría por Láser-Doppler , Masculino , Persona de Mediana Edad , Nitroprusiato/administración & dosificación , Factores de Tiempo
14.
J Womens Health (Larchmt) ; 12(2): 183-92, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12737717

RESUMEN

Obesity, overweight, and a sedentary lifestyle-all common conditions in breast cancer patients-are likely to be associated with poor survival and poor quality of life in women with breast cancer. Diet-related factors are thought to account for about 30% of cancers in developed countries. Most studies of diet and healthcare have focused on the role of single nutrients, foods, or food groups in disease prevention or promotion. Recent cancer guidelines on nutrition and physical activity emphasize diets that promote maintenance of a healthy body weight and a prudent dietary pattern that is low in red and processed meats and high in a variety of vegetables, fruits, and whole grains. Except for dietary fat, few nutritional factors in adult life have been associated with breast cancer. Extensive data from animal model research, international correlations linking fat intake and breast cancer rates, and case-control studies support the hypothesis that a high-fat diet is conducive to the development of breast cancer in postmenopausal women. Conflicting findings from cohort studies, however, have created uncertainty over the role of dietary fat in breast cancer growth and recurrence. Results from large-scale nutritional intervention trials are expected to resolve such issues. As new and improved data on dietary factors and patterns accumulate, dietary guidelines for cancer risk reduction will become more focused.


Asunto(s)
Neoplasias de la Mama/etiología , Conducta Alimentaria , Obesidad/complicaciones , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/prevención & control , Supervivencia sin Enfermedad , Femenino , Hormonas/metabolismo , Humanos , Obesidad/metabolismo , Factores de Riesgo , Tasa de Supervivencia , Estados Unidos/epidemiología
15.
JPEN J Parenter Enteral Nutr ; 28(6): 410-5, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15568287

RESUMEN

BACKGROUND: It has been noted that elevated inflammatory markers, such as tumor necrosis factor-alpha (TNF), soluble TNF receptor II (sTNF-RII), interleukin 6 (IL-6) and C-reactive protein (CRP), are characteristically found in the serum in obese patients. In this study, we examined the correlation of these markers with BMI in nonobese, obese, and morbidly obese individuals to explore this relationship across the broad range of obesity. METHODS: A total of 9 nonobese, including normal and overweight (body mass index [BMI] <30 kg/m2) and 41 obese (BMI > or =30 kg/m2) adults were included in this study. Among obese subjects, 11 subjects were grade I or II obese (BMI > or =30 and <40 kg/m2), and 30 subjects were morbidly obese (grade III obese, BMI > or =40 kg/m2). Serum levels of glucose, insulin, TNF, sTNF-RII, IL-6, and CRP were measured. RESULTS: Obese subjects (BMI > or =30 kg/m2) had significantly higher serum levels of TNF, sTNF-RII, IL-6, and CRP compared with nonobese subjects. Serum levels of sTNF-RII, IL-6, and CRP, but not TNF, were positively correlated with BMI in obese subjects. However, in morbidly obese subjects, only the serum concentrations of IL-6 and CRP remained correlated with BMI, primarily because of this relationship in men. CONCLUSIONS: The present results support evidence that obesity represents an inflammatory state. In morbid obesity, the correlation of only IL-6 and CRP with BMI, particularly in males, suggests that IL-6 may be secreted in an endocrine manner in proportion to the expansion of fat mass particularly in the abdominal region, with a corresponding increase in hepatic production of CRP.


Asunto(s)
Proteína C-Reactiva/metabolismo , Interleucina-6/sangre , Obesidad Mórbida/sangre , Obesidad/sangre , Adulto , Anciano , Glucemia/metabolismo , Índice de Masa Corporal , Peso Corporal/fisiología , Estudios de Casos y Controles , Femenino , Humanos , Insulina/sangre , Masculino , Persona de Mediana Edad , Factor de Necrosis Tumoral alfa/metabolismo
16.
JPEN J Parenter Enteral Nutr ; 26(2): 114-9, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-11871735

RESUMEN

BACKGROUND: Certain patients receiving home total parenteral nutrition (HPN) are likely to develop iron-deficiency anemia because of inadequate absorption or chronic iron loss from gastrointestinal lesions. The objective of this study was to examine the incidence and prevalence of iron deficiency anemia in patients on long-term HPN (>6 months) and to investigate both the efficacy of and rate of adverse reactions to parenteral iron dextran therapy. METHODS: The records of 55 patients treated with HPN for >6 months between January 1, 1994 and December 31, 1999 were examined. RESULTS: Thirty patients (55%) had evidence of iron-deficiency anemia. Ten patients were diagnosed at the initiation of HPN, and in 20 patients, iron deficiency developed after receiving HPN. The time between initiation of HPN and development of anemia ranged from 2 to 97 months (mean 28.8+/-26.2 months). Mild iron loss from the gastrointestinal tract seemed to be the predominant reason for iron deficiency. Regular treatment with small amounts of iron in HPN appeared to be safe and efficacious, with no reported side effects. Total dose infusion of iron was associated with adverse reactions in as many as 25% of these patients, although all reactions were mild and self-limited. CONCLUSIONS: Iron-deficiency anemia is common in patients receiving chronic HPN. Regular small doses of iron in HPN formula, rather than total dose infusion, is the preferred treatment.


Asunto(s)
Anemia Ferropénica/epidemiología , Nutrición Parenteral Total en el Domicilio , Adulto , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Femenino , Enfermedades Gastrointestinales/complicaciones , Hemorragia Gastrointestinal/complicaciones , Humanos , Infusiones Intravenosas , Hierro/administración & dosificación , Hierro/efectos adversos , Masculino , Persona de Mediana Edad , Síndrome del Intestino Corto/complicaciones , Síndrome del Intestino Corto/terapia , Factores de Tiempo
19.
Curr Opin Endocrinol Diabetes Obes ; 17(5): 460-6, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20717020

RESUMEN

PURPOSE OF REVIEW: Metabolic syndrome and cardiovascular diseases are important causes of morbidity and mortality among patients with severe mental illnesses. Atypical or second-generation antipsychotics (SGAs) are associated with obesity and other components of metabolic syndrome, particularly abnormal glucose and lipid metabolism. This review aims to provide a summary of recent evidence on metabolic risks associated with SGAs, current recommendations for metabolic monitoring, and efficacy of treatment options currently available. RECENT FINDINGS: Studies have identified younger, antipsychotic-naive patients with first-episode psychosis as a population vulnerable to adverse metabolic effects from SGAs. These patients gained more weight and developed evident lipid and glucose abnormalities as soon as 8-12 weeks after treatment initiation. Findings are more striking among children and adolescents. The differential effects of various SGAs are well described, with clozapine and olanzapine associated with the highest metabolic risk. In addition to behavioral therapy, emerging data suggest that pharmacological therapy, most notably metformin, is efficacious in the treatment and possibly prevention of SGA-associated metabolic derangements. SUMMARY: More data have become available on the burden from metabolic complications associated with SGAs. New and effective treatment options are required in the near future to improve cardiovascular health in this susceptible population.


Asunto(s)
Antipsicóticos/efectos adversos , Síndrome Metabólico/inducido químicamente , Obesidad/inducido químicamente , Trastornos Psicóticos/tratamiento farmacológico , Antipsicóticos/uso terapéutico , Benzodiazepinas/efectos adversos , Benzodiazepinas/uso terapéutico , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/tratamiento farmacológico , Clozapina/efectos adversos , Clozapina/uso terapéutico , Humanos , Síndrome Metabólico/tratamiento farmacológico , Síndrome Metabólico/metabolismo , Metformina/uso terapéutico , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Olanzapina , Guías de Práctica Clínica como Asunto , Trastornos Psicóticos/metabolismo , Índice de Severidad de la Enfermedad , Aumento de Peso/efectos de los fármacos
20.
Am J Health Promot ; 25(1): 26-9, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20809828

RESUMEN

PURPOSE: Assess whether a convenient care clinic (CCC) medical weight-loss program can promote weight loss. DESIGN: Prospective cohort study with follow-up at 10 weeks. SETTING: A CCC (Lindora Health Clinic) weight-loss program (Lean for Life) based in a retail pharmacy (Rite Aid Pharmacy) in Costa Mesa, California. SUBJECTS: The first 100 people to purchase the weight-loss program. INTERVENTION: A 10-week, $465 medical weight-loss program with individual counseling sessions; a hypocaloric diet of 900 to 1200 kcal/day (25%-30% carbohydrates, 40% protein, 25% fat); and adjunctive pharmacologic treatment, if necessary. MEASURES: We collected data on age, height, weight, visits per week, medication use, comorbid conditions, and weight change. ANALYSIS: Data were analyzed based on length of enrollment and mean percent weight loss. Statistical tests used were t-test and Spearman rank correlation test. RESULTS: Eighty-six subjects had valid data entries for weight change over the 10-week period. Average age was 51.6 years; mean starting body mass index was 30.3. Thirty patients participated for 0 to 4 weeks, 30 for 4 to 9 weeks, and 26 for 10 weeks. Mean percent weight changes for the 0 to 4, 5 to 9, and 10-week groups were -1.6, -6.0, and -8.1, respectively. Forty-five (45%) of the patients achieved medically significant weight loss (> or =5%). CONCLUSION: The study shows that a medical weight-loss program offered at a CCC in a retail pharmacy can produce medically significant weight loss of > or =5%. Further research of collaborations between the retail and medical weight-loss industries is warranted. Study design limitations included selection bias and confounding variables other than the weight-loss program.


Asunto(s)
Instituciones de Atención Ambulatoria/estadística & datos numéricos , Obesidad/terapia , Pérdida de Peso , Adulto , Análisis de Varianza , Índice de Masa Corporal , California , Estudios de Factibilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Actividad Motora , Obesidad/tratamiento farmacológico , Obesidad/rehabilitación , Sobrepeso/terapia , Farmacias/estadística & datos numéricos , Estudios Prospectivos , Estadísticas no Paramétricas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA